منابع مشابه
A new combination therapy in stable angina pectoris.
Ischaemic heart disease is the leading cause of death in high, middle, and low income countries. The improvement in management and survival of heart disease in the last decades, together with an increasingly ageing population, continues to increase the absolute number of patients with heart disease. Optimal medical therapy includes satisfactory antianginal therapy and intensive risk factor modi...
متن کاملTherapy of Stable Angina Pectoris
Case study: A 62-year-old male smoker with type 2 diabetes mellitus and hypertension presents with a 4-month history of exertional chest pain. Physical examination shows a blood pressure of 152/90 mm Hg but is otherwise unremarkable. The ECG is normal, and laboratory tests show a fasting blood glucose value of 110 mg/dL, glycosylated hemoglobin 6.0%, creatinine 1.1 mg/dL, total cholesterol 160,...
متن کاملThe medical therapy of angina pectoris.
The angina pectoris crisis should be treated with nitroglycerin S.L.. In our days as in the 19th century, the non pharmacological therapeutic approach for angina pectoris (per se and to improve the free interval between crises) is still the same. This consists of the reduction of mental and physical stress, to stop smoking, improve light exercise, reduce obesity, and control other risk factors ...
متن کاملRefractory Angina Pectoris: Focus on Cell Therapy
Although medical and surgical treatments often provide adequate solutions for individuals with coronary artery disease, an increasing need exists to develop treatment modalities for those patients with angina who are unresponsive to medical therapy, have serious coronary atherosclerosis, and are not eligible for percutaneous techniques or bypass surgery, a condition known as refractory angina p...
متن کاملTHERAPY AND PREVENTION ANGINA Superiority of combined diltiazem and propranolol therapy for angina pectoris
Twenty-four patients with stable angina were evaluated in a 14 week crossover trial. A single-blind placebo period (baseline 1) was followed by two double-blind periods evaluating maximum tolerated doses of diltiazem (up to 360 mg daily) vs placebo. Over the next 1 to 4 weeks, propranolol was started and increased until clinically documented f-blockade was achieved (baseline 2). The final phase...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 1986
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(86)80501-0